Trial reportBritish journal of clinical pharmacology2008
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up.
Trial report in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.The Cochrane database of systematic reviews · 2016Pooled it
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2013Pooled it
- Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2010Trial
- Serial aqueous VEGF analysis for predicting anti-VEGF treatment outcomes in neovascular glaucoma from diabetic retinopathy: a prospective analysis.BMC ophthalmology · 2026Observational
- Surgical Treatment of Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy in Japanese Patients without the Use of Glaucoma Drainage Devices.Journal of clinical medicine · 2024Article
- Review
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2020Review
- Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience.Clinical ophthalmology (Auckland, N.Z.) · 2017Article
- Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.BMC ophthalmology · 2016Article
- Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.Eye (London, England) · 2016Article
- A review of anti-VEGF agents for proliferative diabetic retinopathy.Eye (London, England) · 2014Review
- The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Experimental diabetes research · 2012Review
- The management of complicated glaucoma.Indian journal of ophthalmology · 2011Review
- Developmental guidance of embryonic corneal innervation: roles of Semaphorin3A and Slit2.Developmental biology · 2010Article
- Intracameral injection of ranibizumab caused regression of iris neovascularisation and clearance of hyphaema in a non-diabetic patient with ischaemic remnant retinal flap in a silicone filled eye.BMJ case reports · 2010Article
- The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).Transactions of the American Ophthalmological Society · 2009Article
- Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.Molecular vision · 2009Article
- [Antiangiogenic treatment for neovascular glaucoma and after filtering surgery].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2009Review
- Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders.Journal of ophthalmic & vision research · 2009Article
- Looking back: editors' pick of 2008.British journal of clinical pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsNeovascular glaucoma (NVG) represents one of the most severe forms of secondary glaucoma, caused by a number of ocular and systemic conditions, which share the common element of retinal ischaemia/hypoxia that initiates the subsequent release of angiogenesis factors, with consequent development of new abnormal vessels through the ciliary body. The aim was to examine the potential efficacy and safety of intravitreal injection of bevacizumab (IVB) (Avastin) in the treatment of NVG in patients who had already undergone the standard retinal ablative procedure.
methodsThis was a prospective pilot trial. Clinical data of 26 eyes from 23 patients, including diagnosis, visual acuity, iris fluorescein angiography stage and intraocular pressure (IOP), were collected. Three injections of bevacizumab were scheduled for each recruited eye at 4-week intervals from the start. All investigations were repeated the day before the IVB (1.25 mg/0.05 ml) and at the 1-, 3-, 6-, 9- and 12-month follow-up.
resultsRegression of corneal oedema together with significant pain reduction was achieved in all eyes already after the first IVB, without any noteworthy improvement of visual acuity. At the end of the scheduled protocol (three IVB), regression of iris neovascularization was documented in all patients, together with significant improvement of visual acuity. The IOP reduction from baseline ranged from 30 to 0 mmHg (12.1 +/- 8 mmHg).
conclusionsIntravitreal bevacizumab, as adjunctive treatment to the standard retinal ablative procedure, seems promising for the management of conditions responsible of retinal ischaemia/hypoxia associated with NVG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.